Iranian patients co-infected with COVID-19 and mucormycosis: the most common predisposing factor, clinical outcomes, laboratory markers and diagnosis, and drug therapies DOI

Hamideh Molaei,

Ehsan Shojaeefar,

Eghlim Nemati

et al.

Infectious Diseases, Journal Year: 2022, Volume and Issue: 54(8), P. 600 - 613

Published: April 7, 2022

The newly emerged pandemic of coronavirus disease-2019 (COVID-19) is the world's main health challenge because infected patients become vulnerable to a variety opportunistic diseases.This study aimed assess clinical outcomes, diagnosis, utilized drug therapies, and ongoing COVID-19 practices in Iranian cases co-infected with mucormycosis.A case-series analysis was conducted presence 10 mucormycosis co-infection (two men eight women; mean age 48.8 years) from March October 2020. Demographic variables, signs/symptoms, comorbidities all were recorded. confirmed reverse transcription polymerase chain reaction (RT-PCR) nasopharyngeal swab tests high-resolution computed tomography (HR-CT)_ scans.All had positive RT-PCR for SARS-CoV-2. Eight history diabetes, while three them exhibited hypertension history. Remarkable laboratory findings elevated fasting blood sugar 6 anaemia four patients. A rhino-orbital-cerebral detected based on HR-CT scans otorhinolaryngological or ophthalmological examinations. Neurological disorders including facial, trigeminal, optic, oculomotor nerve involvement resulted paraesthesia, pain, ptosis, no light perception, blurred vision, papilledema five cases. Maxillary ethmoid sinuses most common sites involvement.Vulnerable comorbidities, any facial involvements, treated by excessive doses glucocorticoids antibiotics should undergo precise examinations during appearance early signs hospitalization diagnose treat using standard care antifungal treatments.

Language: Английский

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India DOI
Valliappan Muthu, Ritesh Agarwal, Atul Patel

et al.

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(9), P. e240 - e253

Published: April 4, 2022

Language: Английский

Citations

68
Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis DOI Creative Commons
Salman Hussain, Abanoub Riad, Ambrish Singh

et al.

Journal of Fungi, Journal Year: 2021, Volume and Issue: 7(11), P. 985 - 985

Published: Nov. 18, 2021

Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has high all-cause mortality rate and imposes significant economic, epidemiological, humanistic burden on patients healthcare system. Evidence from published epidemiological studies showed varying prevalence of COVID-19-associated mucormycosis (CAM). study aims to compute pooled CAM other associated clinical outcomes. MEDLINE, Embase, Cochrane Study Register, WHO databases were scanned retrieve relevant articles until August 2021. All reporting among eligible for inclusion. Two investigators independently screened against selection criteria, extracted data, performed quality assessment using JBI tool. The was primary outcome, diabetes, steroid exposure, outcomes interest. Comprehensive Meta-Analysis software version 2 used performing meta-analysis. meta-analysis comprised six with sample size 52,916 mean age 62.12 ± 9.69 years. duration onset 14.59 6.88 days after diagnosis. (seven cases per 1000 patients) 50 times higher than highest recorded background (0.14 patients). A found 29.6% (95% CI: 17.2-45.9%). Optimal glycemic control judicious use steroids should be approach tackling rising cases.

Language: Английский

Citations

67
Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis DOI Open Access
Atsuyuki Watanabe, Matsuo So, Hayato Mitaka

et al.

Mycopathologia, Journal Year: 2022, Volume and Issue: 187(2-3), P. 271 - 289

Published: March 21, 2022

Language: Английский

Citations

31
Overview of COVID-19-Associated Invasive Fungal Infection DOI Open Access
Akira Shishido, Minu Maria Mathew, John W. Baddley

et al.

Current Fungal Infection Reports, Journal Year: 2022, Volume and Issue: 16(3), P. 87 - 97

Published: July 11, 2022

Language: Английский

Citations

23
Mucormycosis, Past and Present: A Comprehensive Review DOI
Ishita Gupta, Pritika Baranwal, Gagandeep Singh

et al.

Future Microbiology, Journal Year: 2023, Volume and Issue: 18(3), P. 217 - 234

Published: Feb. 1, 2023

Mucormycosis is an emerging opportunistic angioinvasive fungal infection. Predisposing factors such as diabetes, neutropenia, long-term corticosteroid therapy, solid organ transplantation and immunosuppression contribute to its occurrence. This disease was not of significant concern prior the COVID-19 pandemic, but gained prominence due infections in patients. needs special attention coordinated efforts scientific community medical professionals reduce morbidity mortality. Here we present overview epidemiology prevalence mucormycosis pre- post-COVID-19 eras, that contributed abrupt increase COVID-19-associated (CAM), actions taken by regulatory agencies (including Code Mucor CAM registry), existing diagnostic tools management strategies.

Language: Английский

Citations

15
COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma DOI Creative Commons

Sahar Farghly Youssif,

Marwa Mahmoud Abdel Rady,

Ahmed Atef Thabet

et al.

Scientific Reports, Journal Year: 2022, Volume and Issue: 12(1)

Published: June 21, 2022

Abstract Mucormycosis is a life-threatening opportunistic angioinvasive fungal infection. We aimed to describe the frequency, presentations, predictors, and in-hospital outcome of mucormycosis patients in scope CoronaVirusDisease-19 (COVID-19) during third viral pandemic wave. This cross-sectional retrospective study included all who fulfilled criteria with concurrent confirmed covid19 infection admitted Assuit University Hospital between March 2021 July 2021. Overall, 433 definite covid-19 infection, which 33 (7.63%) participants were infected mucormycosis. was predominantly seen males (21 vs. 12; p = 0.01). Diabetes mellitus (35% 63.6%; < 0.001), hypertension (2% vs.45.5%; 0.04), Smoking (26.5% 54.5%; 0.001) significantly higher patients. Inflammatory markers, especially E.S.R., those (p 0.001). The dose steroid intake among (160 mg 40 mg; Except for only three alive by residual 30 died. majority (62%) without alive. Male sex; Steroid misuse; D.M.; Sustained inflammation; Severe significant risk factors univariate analysis; however, smoking raised E.S.R. predictors attaining multivariate analysis.

Language: Английский

Citations

20
Can histopathology predict survival in mucormycosis? A retrospective analysis DOI
Shilpi V. Saxena, Anubhav Singh, Kamal Deep Joshi

et al.

Medical Journal Armed Forces India, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Fungal Biofactories for the Formulation of Nanocomposites for Therapeutic Applications DOI

Krishantinee Gobi,

Norliana Munir,

Shoriya Aruni Abdul Manaf

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Diagnostic Challenges in Fungal Coinfections Associated With Global COVID‐19 DOI Creative Commons
Ariyo Shahin Jafari, Amir Sasan Mozaffari Nejad,

Hossein Faraji

et al.

Scientifica, Journal Year: 2025, Volume and Issue: 2025(1)

Published: Jan. 1, 2025

The early diagnosis of opportunistic infections is a critical concern for patient care worldwide, particularly in the context COVID‐19 pandemic. This review examines challenges and advancements management fungal infections, which have become increasingly prominent during Using multiple sources, including curated databases such as PubMed Scopus, well Google Scholar broader literature searches, we systematically reviewed studies on COVID‐19‐associated with focus candidiasis, mucormycosis, aspergillosis. inclusion criteria encompassed peer‐reviewed articles, clinical case reports, cohort that discussed diagnostic methods, outcomes, treatment responses. Data were extracted analyzed to identify key trends gaps current practices. Given significance infections—particularly selected species—this provides comprehensive analysis beyond. Currently, there no definitive strategy effectively addressing these pathogens, highlighting need continued research innovation. Despite medical technology, continue pose significant accurate diagnosis. pandemic has exacerbated challenges, secondary contributing increased morbidity mortality rates. highlights complexities diagnosing coinfections emphasizes urgent improved strategies. Enhancing detection effective management, viral pandemics. Addressing outlined this requires innovative approaches improve outcomes reduce burden global healthcare systems.

Language: Английский

Citations

0
Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients DOI Creative Commons
Francesca Raffaelli, Eloisa Sofia Tanzarella, Gennaro De Pascale

et al.

Journal of Fungi, Journal Year: 2022, Volume and Issue: 8(4), P. 415 - 415

Published: April 17, 2022

Patients with coronavirus disease 19 (COVID-19) admitted to the intensive care unit (ICU) often develop respiratory fungal infections. The most frequent diseases are COVID-19 associated pulmonary aspergillosis (CAPA), mucormycosis (CAPM) and Pneumocystis jirovecii pneumonia (PCP), latter mostly found in patients both underlying HIV infection. Furthermore, co-infections due less common mold pathogens have been also described. Respiratory infections critically ill promoted by multiple risk factors, including epithelial damage caused infection, mechanical ventilation immunosuppression, mainly induced corticosteroids immunomodulators. In patients, a correct discrimination between colonization infection is challenging, further hampered sampling difficulties low reliability of diagnostic approaches, frequently needing an integration clinical, radiological microbiological features. Several antifungal drugs currently available, but development new molecules reduced toxicity, drug-interactions potentially active on difficult treat strains, highly warranted. Finally, role prophylaxis certain populations still controversial must be investigated.

Language: Английский

Citations

15